May 12, 2014

Coram CVS/specialty infusion services has announced the opening of a new branch pharmacy in El Paso, Texas, that will serve the Big Bend, Panhandle and Permian Basin areas of Texas, as well as southern New Mexico.

May 12, 2014

The National Consumers League on Monday announced the winners of the third annual Script Your Future Medication Adherence Team Challenge for health profession students.

May 12, 2014

Perrigo on Monday announced that it received approval from the Food and Drug Administration for azelastine hydrochloride nasal spray (0.15%), a generic version of Astepro. The drug is indicated for people ages 12 years and older and is used to treat nasal symptoms brought on by seasonal allergies or environmental irritants.

May 12, 2014

With half of all patients not taking their medications as prescribed, efforts to engage patients more effectively and boost adherence rates have become critical for pharmacy leaders. Here, we discuss how CVS Caremark is addressing the challenge with William Shrank, M.D. the company’s chief medical officer for provider innovation and analytics.

May 12, 2014

DSN had the opportunity to sit down and talk with Doug Hebert, Co-Founder and Vice President of RxArmory, and Shelly Mowrey, Vice President of RxArmory about the importance of substance abuse prevention.

May 12, 2014

Actavis on Monday announced that it has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%.

May 9, 2014

Bayer agreed to acquire the consumer care business of U.S. pharmaceutical company Merck for a purchase price of $14.2 billion. The OTC acquisition will give Bayer the global No. 2 position in nonprescription products following recently announced consolidations in this growing healthcare industry segment, and will significantly enhance Bayer’s business across multiple therapeutic categories and geographies. Merck's consumer care business includes such leading brands as Claritin, Coppertone and Dr. Scholl’s. Pro forma sales of the combined businesses in 2013 amounted to $7.4 billion with Merck’s business contributing approximately $2.2 billion.

Upon completion of the acquisition, Bayer is expected to achieve global leadership positions in dermatology and gastrointestinals and advance to the No. 2 position in the cold, allergy, sinus and flu category. Bayer will remain No. 2 in nutritionals and No. 3 in analgesics. Overall, the proposed GlaxoSmithKline-Novartis combination represents the largest consumer health business with about 5.7% share, according to reports. The Bayer/Merck combination comes in second with around 4.5% share. McNeil Consumer rounds out the top three globally with a share just above 4%.

May 9, 2014

CorePharma on Thursday announced the launch of methylphenidate hydrochloride tablets USP, the generic version of Ritalin from Novartis.

May 7, 2014

The pace of annual global spending on oncology medicines — which is approaching the $100 billion threshold — has moderated over the past five years, even as a surge in innovative and targeted therapies has brought new therapeutic options to the growing number of patients being treated for cancer and as survival rates for most tumor types continue to increase, according to a new report released Tuesday by the IMS Institute for Healthcare Informatics.

May 7, 2014

The 46th Annual NCPA Conference on National Legislation and Government Affairs kicked off Wednesday on Capitol Hill, bringing together hundreds of members of the National Community Pharmacists Association to discuss critical community pharmacy issues with members of the Senate and House of Representatives, as well as government officials and political insiders.

May 7, 2014

Symphony Health Solutions last week announced it now offers weekly views of pharmaceutical sales and prescription activity.

May 6, 2014

Alliance Boots on Tuesday announced that it has signed an agreement to acquire Farmacias Ahumada.

May 6, 2014

AstraZeneca on Tuesday announced the Food and Drug Administration approved Epanova (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).

May 6, 2014

The Food and Drug Administration's Nonprescription Drugs Advisory Committee on Friday voted 11-4 opposed to switching Merck's allergy remedy Singulair from Rx-to-OTC, according to an Associated Press report.

May 6, 2014

Pfizer's Nexium 24HR will launch May 27, Pfizer reported in a conference call Monday.

May 6, 2014

Sandoz recently announced that the generic manufacturer continues to advance its biosimilars pipeline that currently has six molecules in the Phase III clinical trial/filing prep phase.

May 6, 2014

Teva Pharmaceutical Industries last week announced results for first quarter 2014 ended March 31.

May 5, 2014

The Generic Pharmaceutical Association on Monday hired Felecia Tan for the role of AVP sciences and regulatory affairs.

May 5, 2014

Kmart Pharmacy has announced that it is working with Diplomat Specialty Pharmacy to give Kmart customers and Shop Your Way members access to specialty medications.

May 5, 2014

Teva Pharmaceutical Industries on Monday announced that the Food and Drug Administration approved Synribo (omacetaxine mepesuccinate) for injection, to include home administration.

May 2, 2014

The Consumer Healthcare Products Association on Wednesday commended Arizona Governor Jan Brewer for signing H.B. 2086 in to law.

April 30, 2014

Empowering its customers with new ways to manage their health, MobileHelp — a provider of mobile Personal Emergency Response System solutions — has launched a new medication reminder application.

April 28, 2014

As lifetime earnings for pharmaceuticals decrease, commercialization expenses increase and payers tighten their belts on reimbursement, life science companies will be faced with shrinking margins over the next few years.

April 28, 2014

Total spending on U.S. medicines increased 1% on a real per capita basis in 2013, while the use of healthcare services rose for the first time in three years, according to a report by the IMS Institute for Healthcare Informatics.